Neurological Biomarkers Market

The neurological biomarkers market is expected to reach USD 9.91 billion by 2030, up from USD 5.53 billion in 2025, at a CAGR of 10.7% between 2025 and 2030. This growth is driven by several key factors, including the rising prevalence of neurological disorders and increased clinical and regulatory recognition.

Key players in the neurological biomarkers industry include Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Johnson & Johnson (US), Quanterix (US), and Banyan Biomarkers, Inc. (US), among others. Companies in the neurological biomarkers market are moving beyond traditional assay development into high-throughput, automated platforms that include advanced protein detection, genomic sequencing for neurodegeneration markers, ultrasensitive immunoassays, and specialized reagents for multi-omic biomarker panels and combination diagnostic workflows. By expanding production capacity and launching integrated hardware-software ecosystems, they aim to strengthen regional dominance and support biomarker programs from early discovery and translational research through clinical trials and routine clinical applications, enabling precision neurology strategies.

To know about the assumptions considered for the study download the pdf brochure

In January 2026, Merck KGaA partnered with Valo Health to address Parkinson's complexity through human data-driven AI models and neurological biomarkers, targeting novel therapies for early detection and progression tracking.

Abbott (US)

Abbott's i-STAT Alinity portfolio and handheld TBI plasma testing system make it a market leader by offering point-of-care genomic and protein profiling for emergency and routine CNS assessment on a portable platform. Assays target critical markers such as GFAP and UCH-L1 for traumatic brain injury, along with neuroinflammatory indicators, enabling rapid triage and monitoring in neurology and trauma settings. Streamlined cartridge-to-result processes, 15-minute results, and collaborations with defense agencies for companion diagnostics fit seamlessly into hospital ER workflows, enabling on-site adoption without reliance on a distant reference lab.

Thermo Fisher Scientific (US)

Thermo Fisher's Olink portfolio and Signature Q100 sequencing system make it a major player in the neurological biomarkers market, delivering comprehensive proteomic profiling on a fully automated platform tailored for research and clinical labs. Current panels, such as the Target 48 Neurodegeneration, cover essential protein biomarkers (e.g., NfL, GFAP, p-tau) across Alzheimer's, Parkinson's, and MS from just 1 µL of plasma or CSF, empowering neurologists to track progression and therapy responses swiftly. With seamless sample-to-insight workflows, rapid turnaround in under 1 day, and pharma partnerships for translational validation using existing lab infrastructure, facilities can readily deploy these non-invasive tests independently rather than outsourcing to specialized centers.

QIAGEN (Germany)

QIAGEN’s existing QIAstat-Dx/NeuMoDx business positions it as a leading player in the space, offering multiplex PCR-based genomic profiling for CNS infections and a portfolio of emerging neurodegenerative markers through its syndromic testing solution. These capabilities enable an infectious neurologist to precisely target therapies in under an hour, using panels that detect DNA/RNA from viral, bacterial, or fungal meningitis/encephalitis, alongside neurofilament surrogate targets.

Market Ranking

The neurological biomarkers market is marked by significant consolidation, with a few large companies, such as Abbott (US), offering the i-STAT Alinity handheld system with TBI plasma cartridges for rapid GFAP/UCH-L1 testing. Such a system would be ideal in ERs and regional hospitals for point-of-care triage. Thermo Fisher Scientific Inc. (US) leads with the Olink Target 48 panel and Signature Q100 sequencer, enabling automated proteomic analysis of NfL, p-tau, and GFAP from small plasma/CSF samples for both high-throughput labs and neuro clinics. QIAGEN (Germany) provides QIAstat-Dx panels with NeuMoDx automation to detect meningitis/encephalitis pathogens by multiplex PCR, supporting rapid syndromic diagnostics in hospitals. Bio-Rad Laboratories, Inc. (US) delivers Droplet Digital PCR and immunoassay kits to accurately measure neurofilaments in research and validation workflows. Merck KGaA (Germany) advances Milliplex panels and AI-linked assays for Parkinson's markers, such as alpha-synuclein, connecting data to pharma trials and care networks.

Related Reports:

Neurological Biomarkers Market by Offering (Consumables, Instruments), Type (Proteomic, Genomic), Application (Alzheimer’s, Parkinson’s), End user (Pharma Companies, Clinical Labs) -Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com